Want to see JP:7776 full AI Analyst Report?
7776 Stock Chart & Stats
¥259.00
-¥7.00(-1.73%)
At close: 4:00 PM EST
¥259.00
-¥7.00(-1.73%)
Day’s Range― - ―
52-Week Range¥200.00 - ¥518.00
Previous CloseN/A
Volume900.50K
Average Volume (3M)621.90K
Market Cap
¥8.99B
Enterprise Value¥7.80B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.70
Next Earnings
Aug 13, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-7.24
Shares Outstanding39,423,820
10 Day Avg. Volume981,780
30 Day Avg. Volume621,903
Financial Highlights & Ratios
PEG Ratio-0.34
Price to Book (P/B)7.08
Price to Sales (P/S)107.39
P/FCF Ratio-8.85
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong Gross MarginsGross margins near 48–69% indicate solid unit economics for CellSeed's products and manufacturing services. Durable gross profitability gives the company structural capacity to absorb R&D and SG&A while scaling, supporting margin recovery if revenue growth resumes.
Conservative LeverageRelatively low debt-to-equity provides balance-sheet flexibility, lowering insolvency and interest risks during extended development cycles. Conservative leverage improves the firm's ability to raise financing for long-term R&D or commercialization without critical near-term solvency pressure.
Niche Regenerative Medicine ExpertiseSpecialization in cell-sheet engineering and regenerative medicine creates a durable, high-barrier competitive position. Deep technical focus and proprietary skills support differentiated product pipelines and CDMO-like services that are harder for generalist competitors to replicate.
Bears Say
Sharp Revenue DeclineA 56.7% revenue decline in 2025 signals materially weakened commercial traction and increases fixed-cost strain. Persistent top-line volatility undermines operating leverage and makes sustainable margin recovery dependent on re-establishing consistent sales or reaching major commercialization milestones.
Persistent Cash BurnConsistent negative operating and free cash flow (≈−¥0.7B to −¥1.02B) shows the business cannot self-fund its operations. Ongoing cash burn increases reliance on external financing, raising dilution and execution risk for long-term development programs and commercialization plans.
Large Operating/net Losses And Declining EquityExtremely negative net margins (~−1,319%) and materially declining shareholder equity reflect sustained unprofitability and potential dilution. Continued losses erode ROE and capital base, limiting reinvestment and increasing the risk that future financing will be needed under less favorable terms.
CellSeed Inc. News
7776 FAQ
What was CellSeed Inc.’s price range in the past 12 months?
CellSeed Inc. lowest stock price was ¥200.00 and its highest was ¥518.00 in the past 12 months.
What is CellSeed Inc.’s market cap?
CellSeed Inc.’s market cap is ¥8.99B.
When is CellSeed Inc.’s upcoming earnings report date?
CellSeed Inc.’s upcoming earnings report date is Aug 13, 2026 which is in 2 days.
How were CellSeed Inc.’s earnings last quarter?
CellSeed Inc. released its earnings results on May 13, 2026. The company reported -¥7.24 earnings per share for the quarter, missing the consensus estimate of N/A by -¥7.24.
Is CellSeed Inc. overvalued?
According to Wall Street analysts CellSeed Inc.’s price is currently Overvalued.
Does CellSeed Inc. pay dividends?
CellSeed Inc. does not currently pay dividends.
What is CellSeed Inc.’s EPS estimate?
CellSeed Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does CellSeed Inc. have?
CellSeed Inc. has 39,423,820 shares outstanding.
What happened to CellSeed Inc.’s price movement after its last earnings report?
CellSeed Inc. reported an EPS of -¥7.24 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.916%.
Which hedge fund is a major shareholder of CellSeed Inc.?
Currently, no hedge funds are holding shares in JP:7776
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
CellSeed Inc.
CellSeed Inc. focuses on pioneering regenerative therapies that utilize cell sheet technology. The company is deeply involved in the research, development, and market introduction of advanced cell-sheet medicine products. Its innovations encompass epithelial cell sheets for repairing the esophagus, as well as both regenerated cartilage sheets and chondrocyte sheets aimed at addressing knee osteoarthritis. Beyond its therapeutic pipeline, CellSeed manufactures and distributes a range of specialized cell cultureware. This includes UpCell, a temperature-responsive cultureware vital for cell-sheet engineering; RepCell, another temperature-sensitive product designed for efficient cell collection; and HydroCell, distinguished by its low cell-binding properties. The firm also provides supporting equipment, such as ThermoPlate III, a heating element constructed from transparent glass, and cellZscope, an automated system for real-time cell monitoring. Additionally, CellSeed offers contract development and manufacturing services. Founded in 2001, the company's main operations are situated in Tokyo, Japan.
Technical Analysis
Healios KK
―
StemRIM Inc.
―
ReproCELL Inc.
―
StemCell Institute
―
Japan Tissue Engineering Co., Ltd.
―